SCHEMBL5544093

SCHEMBL5544093

CCN1C(=O)[N]c2cc(N(C)C)ccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.36
▸ ELANE P08246 2/20 0.35
▸ PSMB5 P28074 1/20 0.35
▸ HSD17B10 Q99714 4/20 0.34
▸ KDM4E B2RXH2 3/20 0.34
▸ HPGD P15428 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ TERT O14746 1/20 0.33
▸ APP P05067 1/20 0.33
▸ PARK7 Q99497 1/20 0.33
▸ IP6K1 Q92551 1/20 0.32
▸ IDO1 P14902 1/20 0.32
▸ TDO2 P48775 1/20 0.32
▸ IDO2 Q6ZQW0 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542560 0.79 ALDH1A1 (0.46) ALDH1A1PSMB5HSD17B10KDM4EHPGD
SCHEMBL4753186 0.76 ALDH1A1 (0.41) ALDH1A1HSD17B10KDM4EHPGDMAPT
SCHEMBL7436460 0.76 ALDH1A1 (0.41) ALDH1A1HSD17B10KDM4EHPGDMAPT
SCHEMBL19404346 0.67 SNCA (0.53) ALDH1A1HSD17B10KDM4EHPGDMAPT
SCHEMBL5542614 0.62 PTGS1 (0.41) ALDH1A1PARK7
SCHEMBL4754016 0.61 ALDH1A1 (0.46) ALDH1A1HSD17B10KDM4EHPGDMAPT
SCHEMBL5544626 0.60 ALDH1A1 (0.53) ALDH1A1MEN1KMT2A
SCHEMBL6013595 0.60 ALDH1A1 (0.46) ALDH1A1HSD17B10KDM4EHPGDMAPT
SCHEMBL23954161 0.59 ALDH1A1 (0.38) ALDH1A1HSD17B10KDM4EHPGDMAPT
SCHEMBL2270251 0.59 ALDH1A1 (0.46) ALDH1A1PSMB5HSD17B10KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885ELANE 3771/4885PSMB5 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback